| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | floppase activity | 4.06e-07 | 16 | 19 | 3 | GO:0140328 | |
| GeneOntologyMolecularFunction | peptide lactyltransferase (CoA-dependent) activity | 8.58e-07 | 2 | 19 | 2 | GO:0120300 | |
| GeneOntologyMolecularFunction | histone H3K27 acetyltransferase activity | 8.58e-07 | 2 | 19 | 2 | GO:0044017 | |
| GeneOntologyMolecularFunction | ATPase-coupled intramembrane lipid transporter activity | 2.36e-06 | 28 | 19 | 3 | GO:0140326 | |
| GeneOntologyMolecularFunction | histone H3K18 acetyltransferase activity | 2.57e-06 | 3 | 19 | 2 | GO:0043993 | |
| GeneOntologyMolecularFunction | phosphatidylserine flippase activity | 8.56e-06 | 5 | 19 | 2 | GO:0140346 | |
| GeneOntologyMolecularFunction | intramembrane lipid transporter activity | 1.48e-05 | 51 | 19 | 3 | GO:0140303 | |
| GeneOntologyMolecularFunction | phosphatidylethanolamine flippase activity | 1.80e-05 | 7 | 19 | 2 | GO:0090555 | |
| GeneOntologyMolecularFunction | aminophospholipid flippase activity | 1.80e-05 | 7 | 19 | 2 | GO:0015247 | |
| GeneOntologyMolecularFunction | phosphatidylserine floppase activity | 3.08e-05 | 9 | 19 | 2 | GO:0090556 | |
| GeneOntologyMolecularFunction | glycerophospholipid flippase activity | 7.75e-05 | 14 | 19 | 2 | GO:0140333 | |
| GeneOntologyMolecularFunction | histone H3 acetyltransferase activity | 8.94e-05 | 15 | 19 | 2 | GO:0010484 | |
| GeneOntologyMolecularFunction | flippase activity | 1.16e-04 | 17 | 19 | 2 | GO:0140327 | |
| GeneOntologyMolecularFunction | peroxisome proliferator activated receptor binding | 1.78e-04 | 21 | 19 | 2 | GO:0042975 | |
| GeneOntologyMolecularFunction | bHLH transcription factor binding | 5.60e-04 | 37 | 19 | 2 | GO:0043425 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 8.04e-04 | 196 | 19 | 3 | GO:0005319 | |
| GeneOntologyMolecularFunction | non-membrane spanning protein tyrosine kinase activity | 8.66e-04 | 46 | 19 | 2 | GO:0004715 | |
| GeneOntologyMolecularFunction | histone acetyltransferase activity | 1.06e-03 | 51 | 19 | 2 | GO:0004402 | |
| GeneOntologyMolecularFunction | transcription coactivator binding | 1.19e-03 | 54 | 19 | 2 | GO:0001223 | |
| GeneOntologyMolecularFunction | peptide-lysine-N-acetyltransferase activity | 1.24e-03 | 55 | 19 | 2 | GO:0061733 | |
| GeneOntologyMolecularFunction | histone modifying activity | 1.26e-03 | 229 | 19 | 3 | GO:0140993 | |
| GeneOntologyMolecularFunction | peptide N-acetyltransferase activity | 1.47e-03 | 60 | 19 | 2 | GO:0034212 | |
| GeneOntologyMolecularFunction | phospholipid transporter activity | 2.22e-03 | 74 | 19 | 2 | GO:0005548 | |
| GeneOntologyMolecularFunction | p53 binding | 2.41e-03 | 77 | 19 | 2 | GO:0002039 | |
| GeneOntologyMolecularFunction | N-acetyltransferase activity | 2.47e-03 | 78 | 19 | 2 | GO:0008080 | |
| GeneOntologyMolecularFunction | damaged DNA binding | 2.85e-03 | 84 | 19 | 2 | GO:0003684 | |
| GeneOntologyMolecularFunction | SMAD binding | 2.99e-03 | 86 | 19 | 2 | GO:0046332 | |
| GeneOntologyMolecularFunction | N-acyltransferase activity | 4.17e-03 | 102 | 19 | 2 | GO:0016410 | |
| GeneOntologyMolecularFunction | acetyltransferase activity | 4.34e-03 | 104 | 19 | 2 | GO:0016407 | |
| GeneOntologyMolecularFunction | transcription coregulator binding | 7.72e-03 | 140 | 19 | 2 | GO:0001221 | |
| GeneOntologyMolecularFunction | ATP hydrolysis activity | 7.97e-03 | 441 | 19 | 3 | GO:0016887 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase activity | 8.26e-03 | 145 | 19 | 2 | GO:0004713 | |
| GeneOntologyMolecularFunction | chromatin DNA binding | 1.08e-02 | 167 | 19 | 2 | GO:0031490 | |
| GeneOntologyMolecularFunction | serine-type endopeptidase activity | 1.38e-02 | 190 | 19 | 2 | GO:0004252 | |
| GeneOntologyMolecularFunction | heparin binding | 1.41e-02 | 192 | 19 | 2 | GO:0008201 | |
| GeneOntologyMolecularFunction | endopeptidase regulator activity | 1.54e-02 | 201 | 19 | 2 | GO:0061135 | |
| GeneOntologyMolecularFunction | serine-type peptidase activity | 1.63e-02 | 207 | 19 | 2 | GO:0008236 | |
| GeneOntologyMolecularFunction | serine hydrolase activity | 1.70e-02 | 212 | 19 | 2 | GO:0017171 | |
| GeneOntologyMolecularFunction | ATP-dependent activity | 1.94e-02 | 614 | 19 | 3 | GO:0140657 | |
| GeneOntologyBiologicalProcess | N-terminal peptidyl-lysine acetylation | 4.82e-06 | 4 | 19 | 2 | GO:0018076 | |
| GeneOntologyBiologicalProcess | aminophospholipid translocation | 1.68e-05 | 7 | 19 | 2 | GO:0140331 | |
| GeneOntologyBiologicalProcess | lipid translocation | 2.19e-05 | 60 | 19 | 3 | GO:0034204 | |
| GeneOntologyBiologicalProcess | regulation of membrane lipid distribution | 2.79e-05 | 65 | 19 | 3 | GO:0097035 | |
| GeneOntologyBiologicalProcess | aminophospholipid transport | 2.88e-05 | 9 | 19 | 2 | GO:0015917 | |
| GeneOntologyBiologicalProcess | N-terminal protein amino acid acetylation | 9.57e-05 | 16 | 19 | 2 | GO:0006474 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to heat | 9.57e-05 | 16 | 19 | 2 | GO:1900034 | |
| GeneOntologyBiologicalProcess | stimulatory C-type lectin receptor signaling pathway | 2.01e-04 | 23 | 19 | 2 | GO:0002223 | |
| GeneOntologyBiologicalProcess | cellular response to lectin | 2.01e-04 | 23 | 19 | 2 | GO:1990858 | |
| GeneOntologyBiologicalProcess | response to lectin | 2.01e-04 | 23 | 19 | 2 | GO:1990840 | |
| GeneOntologyBiologicalProcess | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 2.50e-04 | 347 | 19 | 4 | GO:0090092 | |
| GeneOntologyBiologicalProcess | peptidyl-lysine acetylation | 3.00e-04 | 28 | 19 | 2 | GO:0018394 | |
| GeneOntologyBiologicalProcess | N-terminal protein amino acid modification | 3.22e-04 | 29 | 19 | 2 | GO:0031365 | |
| GeneOntologyBiologicalProcess | positive regulation of cellular response to transforming growth factor beta stimulus | 4.70e-04 | 35 | 19 | 2 | GO:1903846 | |
| GeneOntologyBiologicalProcess | positive regulation of transforming growth factor beta receptor signaling pathway | 4.70e-04 | 35 | 19 | 2 | GO:0030511 | |
| GeneOntologyBiologicalProcess | phospholipid metabolic process | 4.71e-04 | 410 | 19 | 4 | GO:0006644 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to growth factor stimulus | 4.79e-04 | 412 | 19 | 4 | GO:0090287 | |
| GeneOntologyBiologicalProcess | positive regulation of glycoprotein biosynthetic process | 4.97e-04 | 36 | 19 | 2 | GO:0010560 | |
| GeneOntologyBiologicalProcess | positive regulation of glycoprotein metabolic process | 6.14e-04 | 40 | 19 | 2 | GO:1903020 | |
| GeneOntologyBiologicalProcess | transforming growth factor beta receptor superfamily signaling pathway | 6.41e-04 | 445 | 19 | 4 | GO:0141091 | |
| GeneOntologyBiologicalProcess | face morphogenesis | 6.45e-04 | 41 | 19 | 2 | GO:0060325 | |
| GeneOntologyBiologicalProcess | peptide hormone processing | 6.45e-04 | 41 | 19 | 2 | GO:0016486 | |
| GeneOntologyBiologicalProcess | macrophage derived foam cell differentiation | 6.45e-04 | 41 | 19 | 2 | GO:0010742 | |
| GeneOntologyBiologicalProcess | foam cell differentiation | 7.10e-04 | 43 | 19 | 2 | GO:0090077 | |
| GeneOntologyBiologicalProcess | signaling receptor ligand precursor processing | 8.12e-04 | 46 | 19 | 2 | GO:0140448 | |
| GeneOntologyBiologicalProcess | cell surface receptor protein serine/threonine kinase signaling pathway | 8.64e-04 | 482 | 19 | 4 | GO:0007178 | |
| GeneOntologyBiologicalProcess | response to temperature stimulus | 8.69e-04 | 208 | 19 | 3 | GO:0009266 | |
| GeneOntologyBiologicalProcess | head morphogenesis | 8.84e-04 | 48 | 19 | 2 | GO:0060323 | |
| GeneOntologyBiologicalProcess | phospholipid translocation | 1.16e-03 | 55 | 19 | 2 | GO:0045332 | |
| GeneOntologyBiologicalProcess | protein destabilization | 1.20e-03 | 56 | 19 | 2 | GO:0031648 | |
| GeneOntologyBiologicalProcess | protein deacylation | 1.29e-03 | 58 | 19 | 2 | GO:0035601 | |
| GeneOntologyBiologicalProcess | prostate gland development | 1.47e-03 | 62 | 19 | 2 | GO:0030850 | |
| GeneOntologyBiologicalProcess | macromolecule deacylation | 1.52e-03 | 63 | 19 | 2 | GO:0098732 | |
| GeneOntologyBiologicalProcess | face development | 1.52e-03 | 63 | 19 | 2 | GO:0060324 | |
| GeneOntologyBiologicalProcess | body morphogenesis | 1.57e-03 | 64 | 19 | 2 | GO:0010171 | |
| GeneOntologyBiologicalProcess | protein acetylation | 1.77e-03 | 68 | 19 | 2 | GO:0006473 | |
| GeneOntologyBiologicalProcess | positive regulation of striated muscle cell differentiation | 1.77e-03 | 68 | 19 | 2 | GO:0051155 | |
| GeneOntologyBiologicalProcess | regulation of glycoprotein biosynthetic process | 1.82e-03 | 69 | 19 | 2 | GO:0010559 | |
| GeneOntologyCellularComponent | phospholipid-translocating ATPase complex | 7.08e-05 | 14 | 19 | 2 | GO:1990531 | |
| HumanPheno | Aortic isthmus hypoplasia | 1.16e-06 | 2 | 6 | 2 | HP:0034227 | |
| HumanPheno | Plantar crease between first and second toes | 1.16e-06 | 2 | 6 | 2 | HP:0008107 | |
| HumanPheno | High axial triradius | 1.16e-06 | 2 | 6 | 2 | HP:0001042 | |
| HumanPheno | Humoral immunodeficiency | 3.47e-06 | 3 | 6 | 2 | HP:0005363 | |
| HumanPheno | Prominent nasal septum | 3.47e-06 | 3 | 6 | 2 | HP:0005322 | |
| HumanPheno | Radial deviation of thumb terminal phalanx | 3.47e-06 | 3 | 6 | 2 | HP:0005895 | |
| HumanPheno | Laryngeal cartilage malformation | 3.47e-06 | 3 | 6 | 2 | HP:0008752 | |
| HumanPheno | Phobia | 3.47e-06 | 3 | 6 | 2 | HP:5200232 | |
| HumanPheno | Agoraphobia | 3.47e-06 | 3 | 6 | 2 | HP:0000756 | |
| HumanPheno | Trichiasis | 6.93e-06 | 4 | 6 | 2 | HP:0001128 | |
| HumanPheno | Widened distal phalanges | 6.93e-06 | 4 | 6 | 2 | HP:0006200 | |
| HumanPheno | Visceral hemangioma | 6.93e-06 | 4 | 6 | 2 | HP:0410266 | |
| HumanPheno | Talon cusp | 6.93e-06 | 4 | 6 | 2 | HP:0011087 | |
| HumanPheno | Vascular ring | 6.93e-06 | 4 | 6 | 2 | HP:0010775 | |
| HumanPheno | Hepatic hemangioma | 6.93e-06 | 4 | 6 | 2 | HP:0031207 | |
| HumanPheno | Papillary cystadenoma of the epididymis | 1.15e-05 | 5 | 6 | 2 | HP:0009715 | |
| HumanPheno | Supernumerary cusp | 1.15e-05 | 5 | 6 | 2 | HP:0033777 | |
| HumanPheno | Epididymal neoplasm | 1.15e-05 | 5 | 6 | 2 | HP:0030421 | |
| HumanPheno | Short first metatarsal | 1.15e-05 | 5 | 6 | 2 | HP:0010105 | |
| HumanPheno | Abnormal hallux phalanx morphology | 1.35e-05 | 46 | 6 | 3 | HP:0010057 | |
| HumanPheno | Large foramen magnum | 1.73e-05 | 6 | 6 | 2 | HP:0002700 | |
| HumanPheno | Abnormal proximal phalanx morphology of the hand | 1.96e-05 | 52 | 6 | 3 | HP:0009834 | |
| HumanPheno | Deviated nasal septum | 2.42e-05 | 7 | 6 | 2 | HP:0004411 | |
| HumanPheno | Aplasia/hypoplasia of the 1st metatarsal | 3.23e-05 | 8 | 6 | 2 | HP:0010067 | |
| HumanPheno | Aplasia/hypoplasia of proximal toe phalanx | 3.23e-05 | 8 | 6 | 2 | HP:0010203 | |
| HumanPheno | Short phalanx of hallux | 3.23e-05 | 8 | 6 | 2 | HP:0010111 | |
| HumanPheno | Pilomatrixoma | 4.15e-05 | 9 | 6 | 2 | HP:0030434 | |
| HumanPheno | Cervical cord compression | 4.15e-05 | 9 | 6 | 2 | HP:0002341 | |
| HumanPheno | Frontal hirsutism | 5.18e-05 | 10 | 6 | 2 | HP:0011335 | |
| HumanPheno | Abnormal subclavian artery morphology | 6.33e-05 | 11 | 6 | 2 | HP:0031251 | |
| HumanPheno | Hypoplasia of the phalanges of the toes | 7.59e-05 | 12 | 6 | 2 | HP:0010746 | |
| HumanPheno | Facial grimacing | 8.97e-05 | 13 | 6 | 2 | HP:0000273 | |
| HumanPheno | Abnormality of the first metatarsal bone | 8.97e-05 | 13 | 6 | 2 | HP:0010054 | |
| HumanPheno | Aplasia/Hypoplasia of the phalanges of the hallux | 8.97e-05 | 13 | 6 | 2 | HP:0010058 | |
| HumanPheno | Keloids | 8.97e-05 | 13 | 6 | 2 | HP:0010562 | |
| HumanPheno | Deviation of the hallux | 9.60e-05 | 88 | 6 | 3 | HP:0010051 | |
| HumanPheno | Parietal foramina | 1.05e-04 | 14 | 6 | 2 | HP:0002697 | |
| HumanPheno | Duplication of phalanx of hallux | 1.05e-04 | 14 | 6 | 2 | HP:0010066 | |
| HumanPheno | Abnormality of toe proximal phalanx | 1.05e-04 | 14 | 6 | 2 | HP:0010184 | |
| HumanPheno | Hypoplastic aortic arch | 1.05e-04 | 14 | 6 | 2 | HP:0012304 | |
| HumanPheno | Social and occupational deterioration | 1.21e-04 | 15 | 6 | 2 | HP:0007086 | |
| HumanPheno | Duplication of phalanx of toe | 1.21e-04 | 15 | 6 | 2 | HP:0010181 | |
| HumanPheno | Square face | 1.38e-04 | 16 | 6 | 2 | HP:0000321 | |
| HumanPheno | Premature thelarche | 1.56e-04 | 17 | 6 | 2 | HP:0010314 | |
| HumanPheno | Facial hirsutism | 1.75e-04 | 18 | 6 | 2 | HP:0009937 | |
| HumanPheno | Skin appendage neoplasm | 1.75e-04 | 18 | 6 | 2 | HP:0012842 | |
| HumanPheno | Absent earlobe | 2.18e-04 | 20 | 6 | 2 | HP:0000387 | |
| HumanPheno | Deviation of toes | 2.30e-04 | 118 | 6 | 3 | HP:0100498 | |
| HumanPheno | Localized hirsutism | 2.40e-04 | 21 | 6 | 2 | HP:0009889 | |
| HumanPheno | Deep plantar creases | 2.40e-04 | 21 | 6 | 2 | HP:0001869 | |
| HumanPheno | Corneal scarring | 2.40e-04 | 21 | 6 | 2 | HP:0000559 | |
| HumanPheno | Short thumb | 2.87e-04 | 127 | 6 | 3 | HP:0009778 | |
| HumanPheno | Abnormal foramen magnum morphology | 2.89e-04 | 23 | 6 | 2 | HP:0002699 | |
| HumanPheno | Agenesis of permanent teeth | 2.89e-04 | 23 | 6 | 2 | HP:0006349 | |
| HumanPheno | Abnormal toe phalanx morphology | 3.07e-04 | 130 | 6 | 3 | HP:0010161 | |
| HumanPheno | Simple ear | 3.15e-04 | 24 | 6 | 2 | HP:0020206 | |
| HumanPheno | Broad hallux phalanx | 3.15e-04 | 24 | 6 | 2 | HP:0010059 | |
| HumanPheno | Shawl scrotum | 3.43e-04 | 25 | 6 | 2 | HP:0000049 | |
| HumanPheno | Minor feet anomalies | 3.71e-04 | 26 | 6 | 2 | HP:0010613 | |
| HumanPheno | Abnormal feet morphology | 3.71e-04 | 26 | 6 | 2 | HP:0010611 | |
| HumanPheno | Phonophobia | 3.71e-04 | 26 | 6 | 2 | HP:0002183 | |
| HumanPheno | Perimembranous ventricular septal defect | 3.71e-04 | 26 | 6 | 2 | HP:0011682 | |
| HumanPheno | Flared iliac wing | 4.01e-04 | 27 | 6 | 2 | HP:0002869 | |
| HumanPheno | Broad distal phalanx of finger | 4.01e-04 | 27 | 6 | 2 | HP:0009836 | |
| HumanPheno | Abnormal scrotum morphology | 4.07e-04 | 143 | 6 | 3 | HP:0000045 | |
| HumanPheno | Short columella | 4.63e-04 | 29 | 6 | 2 | HP:0002000 | |
| HumanPheno | Abnormal parietal bone morphology | 4.63e-04 | 29 | 6 | 2 | HP:0002696 | |
| HumanPheno | Broad eyebrow | 4.63e-04 | 29 | 6 | 2 | HP:0011229 | |
| HumanPheno | Aplasia/Hypoplasia of the thumb | 4.69e-04 | 150 | 6 | 3 | HP:0009601 | |
| HumanPheno | Avascular necrosis of the capital femoral epiphysis | 4.96e-04 | 30 | 6 | 2 | HP:0005743 | |
| HumanPheno | Abnormal epididymis morphology | 4.96e-04 | 30 | 6 | 2 | HP:0009714 | |
| HumanPheno | Preaxial foot polydactyly | 4.96e-04 | 30 | 6 | 2 | HP:0001841 | |
| HumanPheno | Hypoplastic iliac wing | 5.30e-04 | 31 | 6 | 2 | HP:0002866 | |
| HumanPheno | Recurrent urinary tract infections | 5.37e-04 | 157 | 6 | 3 | HP:0000010 | |
| HumanPheno | Urinary tract infections | 5.57e-04 | 159 | 6 | 3 | HP:0000094 | |
| HumanPheno | Urinary bladder inflammation | 5.57e-04 | 159 | 6 | 3 | HP:0100577 | |
| HumanPheno | Abnormal pulmonary valve physiology | 5.99e-04 | 163 | 6 | 3 | HP:0031654 | |
| HumanPheno | Frontal upsweep of hair | 6.01e-04 | 33 | 6 | 2 | HP:0002236 | |
| HumanPheno | Syringomyelia | 6.01e-04 | 33 | 6 | 2 | HP:0003396 | |
| HumanPheno | Abnormal branching pattern of the aortic arch | 6.01e-04 | 33 | 6 | 2 | HP:0011587 | |
| HumanPheno | Aspiration | 6.38e-04 | 34 | 6 | 2 | HP:0002835 | |
| HumanPheno | Abnormal number of permanent teeth | 6.76e-04 | 35 | 6 | 2 | HP:0011044 | |
| HumanPheno | Hydrocele testis | 7.16e-04 | 36 | 6 | 2 | HP:0000034 | |
| HumanPheno | Disturbance of facial expression | 7.16e-04 | 36 | 6 | 2 | HP:0005324 | |
| HumanPheno | Abnormality of the distal phalanx of the thumb | 7.16e-04 | 36 | 6 | 2 | HP:0009617 | |
| HumanPheno | Aplasia/Hypoplasia of the phalanges of the toes | 7.16e-04 | 36 | 6 | 2 | HP:0010173 | |
| HumanPheno | Nasolacrimal duct obstruction | 7.16e-04 | 36 | 6 | 2 | HP:0000579 | |
| HumanPheno | Abnormal distal phalanx morphology of finger | 7.26e-04 | 174 | 6 | 3 | HP:0009832 | |
| HumanPheno | Auditory sensitivity | 7.56e-04 | 37 | 6 | 2 | HP:0025112 | |
| HumanPheno | Accessory spleen | 7.56e-04 | 37 | 6 | 2 | HP:0001747 | |
| HumanPheno | Auditory hypersensitivity | 7.56e-04 | 37 | 6 | 2 | HP:5200060 | |
| HumanPheno | Nasogastric tube feeding in infancy | 7.56e-04 | 37 | 6 | 2 | HP:0011470 | |
| HumanPheno | Natal tooth | 7.98e-04 | 38 | 6 | 2 | HP:0000695 | |
| HumanPheno | Short hallux | 7.98e-04 | 38 | 6 | 2 | HP:0010109 | |
| HumanPheno | Capillary hemangioma | 8.40e-04 | 39 | 6 | 2 | HP:0005306 | |
| HumanPheno | Cellular immunodeficiency | 8.40e-04 | 39 | 6 | 2 | HP:0005374 | |
| HumanPheno | Poor coordination | 8.40e-04 | 39 | 6 | 2 | HP:0002370 | |
| HumanPheno | Abnormal hair whorl | 9.75e-04 | 42 | 6 | 2 | HP:0010721 | |
| HumanPheno | Juvenile aseptic necrosis | 1.02e-03 | 43 | 6 | 2 | HP:0100323 | |
| HumanPheno | Aplasia/Hypoplasia of the hallux | 1.02e-03 | 43 | 6 | 2 | HP:0008362 | |
| MousePheno | thin myocardium compact layer | 2.20e-05 | 46 | 17 | 3 | MP:0004057 | |
| MousePheno | abnormal myocardium compact layer morphology | 6.82e-05 | 67 | 17 | 3 | MP:0004056 | |
| MousePheno | increased organ/body region tumor incidence | 8.21e-05 | 395 | 17 | 5 | MP:0010274 | |
| MousePheno | abnormal organ/body region tumor incidence | 8.82e-05 | 401 | 17 | 5 | MP:0013152 | |
| MousePheno | lethality throughout fetal growth and development, incomplete penetrance | 9.74e-05 | 208 | 17 | 4 | MP:0011109 | |
| MousePheno | abnormal respiratory system morphology | 1.14e-04 | 1027 | 17 | 7 | MP:0002132 | |
| MousePheno | abnormal heart atrium morphology | 1.48e-04 | 232 | 17 | 4 | MP:0003105 | |
| MousePheno | atrial septal defect | 1.54e-04 | 88 | 17 | 3 | MP:0010403 | |
| MousePheno | perimembraneous ventricular septal defect | 1.75e-04 | 92 | 17 | 3 | MP:0010418 | |
| MousePheno | abnormal interventricular septum membranous part morphology | 1.81e-04 | 93 | 17 | 3 | MP:0008823 | |
| MousePheno | abnormal lung morphology | 1.96e-04 | 767 | 17 | 6 | MP:0001175 | |
| MousePheno | ventricular septal defect | 2.33e-04 | 261 | 17 | 4 | MP:0010402 | |
| MousePheno | thin ventricle myocardium compact layer | 2.61e-04 | 20 | 17 | 2 | MP:0010556 | |
| MousePheno | abnormal interatrial septum morphology | 2.74e-04 | 107 | 17 | 3 | MP:0000282 | |
| MousePheno | increased tumor incidence | 3.26e-04 | 530 | 17 | 5 | MP:0002020 | |
| MousePheno | anemia | 4.28e-04 | 306 | 17 | 4 | MP:0001577 | |
| MousePheno | abnormal umbilical cord blood vessel morphology | 4.45e-04 | 26 | 17 | 2 | MP:0012300 | |
| MousePheno | abnormal interventricular septum morphology | 6.51e-04 | 342 | 17 | 4 | MP:0000281 | |
| MousePheno | abnormal tumor incidence | 7.47e-04 | 635 | 17 | 5 | MP:0002019 | |
| MousePheno | abnormal tumor susceptibility | 8.30e-04 | 650 | 17 | 5 | MP:0002166 | |
| MousePheno | oligodactyly | 1.00e-03 | 39 | 17 | 2 | MP:0000565 | |
| MousePheno | abnormal heart septum morphology | 1.04e-03 | 388 | 17 | 4 | MP:0006113 | |
| MousePheno | increased megakaryocyte cell number | 1.34e-03 | 45 | 17 | 2 | MP:0008254 | |
| MousePheno | abnormal umbilical cord morphology | 1.40e-03 | 46 | 17 | 2 | MP:0001725 | |
| MousePheno | increased nervous system tumor incidence | 1.40e-03 | 46 | 17 | 2 | MP:0010281 | |
| MousePheno | neoplasm | 1.55e-03 | 747 | 17 | 5 | MP:0002006 | |
| MousePheno | lethality throughout fetal growth and development | 1.59e-03 | 435 | 17 | 4 | MP:0006208 | |
| MousePheno | abnormal nose morphology | 1.72e-03 | 201 | 17 | 3 | MP:0002233 | |
| Domain | - | 9.80e-07 | 2 | 19 | 2 | 1.10.246.20 | |
| Domain | zf-TAZ | 9.80e-07 | 2 | 19 | 2 | PF02135 | |
| Domain | ZF_TAZ | 9.80e-07 | 2 | 19 | 2 | PS50134 | |
| Domain | Nuc_rcpt_coact_CREBbp | 9.80e-07 | 2 | 19 | 2 | IPR014744 | |
| Domain | HAT_KAT11 | 9.80e-07 | 2 | 19 | 2 | PF08214 | |
| Domain | KIX | 9.80e-07 | 2 | 19 | 2 | PS50952 | |
| Domain | ZnF_TAZ | 9.80e-07 | 2 | 19 | 2 | SM00551 | |
| Domain | CBP_P300_HAT | 9.80e-07 | 2 | 19 | 2 | IPR031162 | |
| Domain | Histone_AcTrfase_Rtt109/CBP | 9.80e-07 | 2 | 19 | 2 | IPR013178 | |
| Domain | DUF902 | 9.80e-07 | 2 | 19 | 2 | PF06001 | |
| Domain | - | 9.80e-07 | 2 | 19 | 2 | 1.20.1020.10 | |
| Domain | RING_CBP-p300 | 9.80e-07 | 2 | 19 | 2 | IPR010303 | |
| Domain | KAT11 | 9.80e-07 | 2 | 19 | 2 | SM01250 | |
| Domain | - | 9.80e-07 | 2 | 19 | 2 | 1.10.1630.10 | |
| Domain | Znf_TAZ | 9.80e-07 | 2 | 19 | 2 | IPR000197 | |
| Domain | KIX_dom | 9.80e-07 | 2 | 19 | 2 | IPR003101 | |
| Domain | Creb_binding | 9.80e-07 | 2 | 19 | 2 | PF09030 | |
| Domain | KIX | 9.80e-07 | 2 | 19 | 2 | PF02172 | |
| Domain | CBP_P300_HAT | 9.80e-07 | 2 | 19 | 2 | PS51727 | |
| Domain | Nuc_rcpt_coact | 1.47e-05 | 6 | 19 | 2 | IPR009110 | |
| Domain | Peptidase_S8_Asp-AS | 1.47e-05 | 6 | 19 | 2 | IPR023827 | |
| Domain | PrprotnconvertsP | 2.05e-05 | 7 | 19 | 2 | IPR002884 | |
| Domain | P_proprotein | 2.05e-05 | 7 | 19 | 2 | PF01483 | |
| Domain | S8_pro-domain | 2.05e-05 | 7 | 19 | 2 | IPR032815 | |
| Domain | - | 2.05e-05 | 7 | 19 | 2 | 3.30.70.850 | |
| Domain | S8_pro-domain | 2.05e-05 | 7 | 19 | 2 | PF16470 | |
| Domain | Peptidase_S8_His-AS | 3.51e-05 | 9 | 19 | 2 | IPR022398 | |
| Domain | Peptidase_S8_Ser-AS | 3.51e-05 | 9 | 19 | 2 | IPR023828 | |
| Domain | Peptidase_S8_subtilisin-rel | 4.39e-05 | 10 | 19 | 2 | IPR015500 | |
| Domain | SUBTILASE_ASP | 4.39e-05 | 10 | 19 | 2 | PS00136 | |
| Domain | SUBTILASE_HIS | 4.39e-05 | 10 | 19 | 2 | PS00137 | |
| Domain | SUBTILASE_SER | 4.39e-05 | 10 | 19 | 2 | PS00138 | |
| Domain | Peptidase_S8 | 5.36e-05 | 11 | 19 | 2 | PF00082 | |
| Domain | - | 5.36e-05 | 11 | 19 | 2 | 3.40.50.200 | |
| Domain | Peptidase_S8/S53_dom | 5.36e-05 | 11 | 19 | 2 | IPR000209 | |
| Domain | P_typ_ATPase_c | 8.86e-05 | 14 | 19 | 2 | IPR032630 | |
| Domain | P-type_ATPase_N | 8.86e-05 | 14 | 19 | 2 | IPR032631 | |
| Domain | P-type_ATPase_IV | 8.86e-05 | 14 | 19 | 2 | IPR006539 | |
| Domain | PhoLip_ATPase_C | 8.86e-05 | 14 | 19 | 2 | PF16212 | |
| Domain | PhoLip_ATPase_N | 8.86e-05 | 14 | 19 | 2 | PF16209 | |
| Domain | Propept_inh | 1.32e-04 | 17 | 19 | 2 | IPR009020 | |
| Domain | ZF_ZZ_2 | 1.49e-04 | 18 | 19 | 2 | PS50135 | |
| Domain | Furin_repeat | 1.49e-04 | 18 | 19 | 2 | IPR006212 | |
| Domain | ZF_ZZ_1 | 1.49e-04 | 18 | 19 | 2 | PS01357 | |
| Domain | ZZ | 1.49e-04 | 18 | 19 | 2 | PF00569 | |
| Domain | FU | 1.49e-04 | 18 | 19 | 2 | SM00261 | |
| Domain | Znf_ZZ | 1.66e-04 | 19 | 19 | 2 | IPR000433 | |
| Domain | ZnF_ZZ | 1.66e-04 | 19 | 19 | 2 | SM00291 | |
| Domain | Bromodomain_CS | 3.14e-04 | 26 | 19 | 2 | IPR018359 | |
| Domain | - | 4.78e-04 | 32 | 19 | 2 | 2.70.150.10 | |
| Domain | - | 4.78e-04 | 32 | 19 | 2 | 3.40.1110.10 | |
| Domain | ATPase_P-typ_cyto_domN | 5.72e-04 | 35 | 19 | 2 | IPR023299 | |
| Domain | ATPase_P-typ_P_site | 6.05e-04 | 36 | 19 | 2 | IPR018303 | |
| Domain | P_typ_ATPase | 6.05e-04 | 36 | 19 | 2 | IPR001757 | |
| Domain | ATPASE_E1_E2 | 6.05e-04 | 36 | 19 | 2 | PS00154 | |
| Domain | ATPase_P-typ_transduc_dom_A | 6.39e-04 | 37 | 19 | 2 | IPR008250 | |
| Domain | E1-E2_ATPase | 6.39e-04 | 37 | 19 | 2 | PF00122 | |
| Domain | BROMODOMAIN_1 | 6.39e-04 | 37 | 19 | 2 | PS00633 | |
| Domain | Bromodomain | 6.74e-04 | 38 | 19 | 2 | PF00439 | |
| Domain | BROMODOMAIN_2 | 7.85e-04 | 41 | 19 | 2 | PS50014 | |
| Domain | BROMO | 8.24e-04 | 42 | 19 | 2 | SM00297 | |
| Domain | Bromodomain | 8.24e-04 | 42 | 19 | 2 | IPR001487 | |
| Domain | - | 8.24e-04 | 42 | 19 | 2 | 1.20.920.10 | |
| Domain | - | 1.90e-03 | 64 | 19 | 2 | 3.40.50.1000 | |
| Domain | - | 2.47e-03 | 73 | 19 | 2 | 2.60.120.260 | |
| Domain | HAD-like_dom | 2.88e-03 | 79 | 19 | 2 | IPR023214 | |
| Domain | Galactose-bd-like | 4.05e-03 | 94 | 19 | 2 | IPR008979 | |
| Pathway | BIOCARTA_PELP1_PATHWAY | 7.84e-06 | 5 | 13 | 2 | MM1575 | |
| Pathway | REACTOME_NFE2L2_REGULATING_INFLAMMATION_ASSOCIATED_GENES | 7.84e-06 | 5 | 13 | 2 | M48020 | |
| Pathway | REACTOME_LRR_FLII_INTERACTING_PROTEIN_1_LRRFIP1_ACTIVATES_TYPE_I_IFN_PRODUCTION | 7.84e-06 | 5 | 13 | 2 | M27228 | |
| Pathway | REACTOME_NFE2L2_REGULATING_ER_STRESS_ASSOCIATED_GENES | 7.84e-06 | 5 | 13 | 2 | M48023 | |
| Pathway | BIOCARTA_PELP1_PATHWAY | 1.18e-05 | 6 | 13 | 2 | M22062 | |
| Pathway | BIOCARTA_PPARG_PATHWAY | 1.64e-05 | 7 | 13 | 2 | MM1573 | |
| Pathway | BIOCARTA_PPARG_PATHWAY | 2.19e-05 | 8 | 13 | 2 | M22058 | |
| Pathway | REACTOME_NFE2L2_REGULATING_MDR_ASSOCIATED_ENZYMES | 2.19e-05 | 8 | 13 | 2 | M48022 | |
| Pathway | REACTOME_REGULATION_OF_NFE2L2_GENE_EXPRESSION | 2.19e-05 | 8 | 13 | 2 | M48024 | |
| Pathway | REACTOME_NFE2L2_REGULATES_PENTOSE_PHOSPHATE_PATHWAY_GENES | 2.19e-05 | 8 | 13 | 2 | M46443 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR3_IRF3_SIGNALING_PATHWAY | 2.82e-05 | 9 | 13 | 2 | M47451 | |
| Pathway | REACTOME_REGULATION_OF_FOXO_TRANSCRIPTIONAL_ACTIVITY_BY_ACETYLATION | 3.52e-05 | 10 | 13 | 2 | M27945 | |
| Pathway | BIOCARTA_CARM1_PATHWAY | 4.30e-05 | 11 | 13 | 2 | MM1521 | |
| Pathway | REACTOME_NFE2L2_REGULATING_TUMORIGENIC_GENES | 4.30e-05 | 11 | 13 | 2 | M48021 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_BY_HYPOXIA_INDUCIBLE_FACTOR | 4.30e-05 | 11 | 13 | 2 | M26924 | |
| Pathway | BIOCARTA_CARM1_PATHWAY | 5.15e-05 | 12 | 13 | 2 | M7968 | |
| Pathway | REACTOME_ACTIVATION_OF_THE_TFAP2_AP_2_FAMILY_OF_TRANSCRIPTION_FACTORS | 5.15e-05 | 12 | 13 | 2 | M27765 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 7.10e-05 | 14 | 13 | 2 | M27808 | |
| Pathway | BIOCARTA_RELA_PATHWAY | 8.19e-05 | 15 | 13 | 2 | MM1339 | |
| Pathway | BIOCARTA_RELA_PATHWAY | 8.19e-05 | 15 | 13 | 2 | M10183 | |
| Pathway | BIOCARTA_PITX2_PATHWAY | 8.19e-05 | 15 | 13 | 2 | MM1439 | |
| Pathway | REACTOME_TRAF3_DEPENDENT_IRF_ACTIVATION_PATHWAY | 8.19e-05 | 15 | 13 | 2 | M953 | |
| Pathway | BIOCARTA_IL7_PATHWAY | 9.35e-05 | 16 | 13 | 2 | M1296 | |
| Pathway | BIOCARTA_IL7_PATHWAY | 9.35e-05 | 16 | 13 | 2 | MM1420 | |
| Pathway | BIOCARTA_PITX2_PATHWAY | 9.35e-05 | 16 | 13 | 2 | M8516 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS | 9.35e-05 | 16 | 13 | 2 | M27121 | |
| Pathway | REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_CELL_DEATH_GENES | 9.35e-05 | 16 | 13 | 2 | M27940 | |
| Pathway | WP_IL6_SIGNALING_PATHWAY | 9.41e-05 | 100 | 13 | 3 | MM15826 | |
| Pathway | BIOCARTA_TGFB_PATHWAY | 1.06e-04 | 17 | 13 | 2 | MM1509 | |
| Pathway | REACTOME_ZYGOTIC_GENOME_ACTIVATION_ZGA | 1.06e-04 | 17 | 13 | 2 | M48025 | |
| Pathway | REACTOME_RORA_ACTIVATES_GENE_EXPRESSION | 1.19e-04 | 18 | 13 | 2 | M26942 | |
| Pathway | BIOCARTA_TGFB_PATHWAY | 1.33e-04 | 19 | 13 | 2 | M18933 | |
| Pathway | REACTOME_NFE2L2_REGULATING_ANTI_OXIDANT_DETOXIFICATION_ENZYMES | 1.33e-04 | 19 | 13 | 2 | M46442 | |
| Pathway | REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 1.48e-04 | 20 | 13 | 2 | M27881 | |
| Pathway | WP_HEMATOPOIETIC_STEM_CELL_GENE_REGULATION_BY_GABP_ALPHABETA_COMPLEX | 1.63e-04 | 21 | 13 | 2 | M39593 | |
| Pathway | REACTOME_CD209_DC_SIGN_SIGNALING | 1.63e-04 | 21 | 13 | 2 | M27485 | |
| Pathway | BIOCARTA_NTHI_PATHWAY | 1.79e-04 | 22 | 13 | 2 | MM1443 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 1.79e-04 | 22 | 13 | 2 | MM1370 | |
| Pathway | BIOCARTA_NTHI_PATHWAY | 1.96e-04 | 23 | 13 | 2 | M2821 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 2.14e-04 | 24 | 13 | 2 | M13404 | |
| Pathway | REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 2.33e-04 | 25 | 13 | 2 | M27880 | |
| Pathway | BIOCARTA_CARM_ER_PATHWAY | 2.52e-04 | 26 | 13 | 2 | M2499 | |
| Pathway | PID_HDAC_CLASSIII_PATHWAY | 2.52e-04 | 26 | 13 | 2 | M32 | |
| Pathway | REACTOME_ATTENUATION_PHASE | 2.93e-04 | 28 | 13 | 2 | M27254 | |
| Pathway | PID_RETINOIC_ACID_PATHWAY | 3.37e-04 | 30 | 13 | 2 | M207 | |
| Pathway | REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION | 3.37e-04 | 30 | 13 | 2 | M936 | |
| Pathway | WP_INITIATION_OF_TRANSCRIPTION_AND_TRANSLATION_ELONGATION_AT_THE_HIV1_LTR | 3.83e-04 | 32 | 13 | 2 | M39521 | |
| Pathway | WP_TYPE_2_PAPILLARY_RENAL_CELL_CARCINOMA | 4.33e-04 | 34 | 13 | 2 | M39771 | |
| Pathway | PID_HIF2PATHWAY | 4.33e-04 | 34 | 13 | 2 | M44 | |
| Pathway | REACTOME_EVASION_BY_RSV_OF_HOST_INTERFERON_RESPONSES | 4.59e-04 | 35 | 13 | 2 | M48246 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_THE_AP_2_TFAP2_FAMILY_OF_TRANSCRIPTION_FACTORS | 5.42e-04 | 38 | 13 | 2 | M27757 | |
| Pathway | REACTOME_HSF1_DEPENDENT_TRANSACTIVATION | 5.42e-04 | 38 | 13 | 2 | M27255 | |
| Pathway | PID_FOXM1_PATHWAY | 6.00e-04 | 40 | 13 | 2 | M176 | |
| Pathway | PID_IFNG_PATHWAY | 6.00e-04 | 40 | 13 | 2 | M161 | |
| Pathway | REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT | 6.62e-04 | 42 | 13 | 2 | M17541 | |
| Pathway | PID_HNF3A_PATHWAY | 7.27e-04 | 44 | 13 | 2 | M285 | |
| Pathway | REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS | 7.27e-04 | 44 | 13 | 2 | M27295 | |
| Pathway | KEGG_NOTCH_SIGNALING_PATHWAY | 8.29e-04 | 47 | 13 | 2 | M7946 | |
| Pathway | PID_HES_HEY_PATHWAY | 8.65e-04 | 48 | 13 | 2 | M288 | |
| Pathway | REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 8.65e-04 | 48 | 13 | 2 | M611 | |
| Pathway | PID_FOXO_PATHWAY | 9.01e-04 | 49 | 13 | 2 | M136 | |
| Pathway | REACTOME_HEME_SIGNALING | 9.01e-04 | 49 | 13 | 2 | M41832 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH3 | 9.01e-04 | 49 | 13 | 2 | M618 | |
| Pathway | BIOCARTA_PPARA_PATHWAY | 1.01e-03 | 52 | 13 | 2 | M2404 | |
| Pathway | PID_NFAT_3PATHWAY | 1.05e-03 | 53 | 13 | 2 | M113 | |
| Pathway | PID_AR_TF_PATHWAY | 1.05e-03 | 53 | 13 | 2 | M151 | |
| Pathway | WP_TGFBETA_SIGNALING_PATHWAY | 1.05e-03 | 53 | 13 | 2 | MM15880 | |
| Pathway | WP_TGFBETA_RECEPTOR_SIGNALING | 1.13e-03 | 55 | 13 | 2 | M39351 | |
| Pathway | REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES | 1.13e-03 | 55 | 13 | 2 | M971 | |
| Pathway | REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES | 1.22e-03 | 57 | 13 | 2 | MM15643 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER | 1.26e-03 | 58 | 13 | 2 | M29616 | |
| Pathway | WP_TGFBETA_RECEPTOR_SIGNALING_IN_SKELETAL_DYSPLASIAS | 1.30e-03 | 59 | 13 | 2 | M39886 | |
| Pathway | PID_P53_REGULATION_PATHWAY | 1.30e-03 | 59 | 13 | 2 | M261 | |
| Pathway | REACTOME_CYTOSOLIC_SENSORS_OF_PATHOGEN_ASSOCIATED_DNA | 1.53e-03 | 64 | 13 | 2 | M27046 | |
| Pathway | WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA | 1.58e-03 | 65 | 13 | 2 | M39682 | |
| Pathway | PID_RB_1PATHWAY | 1.58e-03 | 65 | 13 | 2 | M279 | |
| Pathway | PID_HIF1_TFPATHWAY | 1.63e-03 | 66 | 13 | 2 | M255 | |
| Pathway | PID_HDAC_CLASSI_PATHWAY | 1.63e-03 | 66 | 13 | 2 | M101 | |
| Pathway | REACTOME_FOXO_MEDIATED_TRANSCRIPTION | 1.63e-03 | 66 | 13 | 2 | M27938 | |
| Pathway | WP_UROTENSINIIMEDIATED_SIGNALING | 1.78e-03 | 69 | 13 | 2 | M48052 | |
| Pathway | REACTOME_FORMATION_OF_PARAXIAL_MESODERM | 1.78e-03 | 69 | 13 | 2 | M46439 | |
| Pathway | KEGG_LONG_TERM_POTENTIATION | 1.83e-03 | 70 | 13 | 2 | M3115 | |
| Pathway | KEGG_RENAL_CELL_CARCINOMA | 1.83e-03 | 70 | 13 | 2 | M13266 | |
| Pathway | REACTOME_CIRCADIAN_CLOCK | 1.83e-03 | 70 | 13 | 2 | M938 | |
| Pathway | PID_E2F_PATHWAY | 1.99e-03 | 73 | 13 | 2 | M40 | |
| Pathway | KEGG_ADHERENS_JUNCTION | 1.99e-03 | 73 | 13 | 2 | M638 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 2.04e-03 | 74 | 13 | 2 | M616 | |
| Pathway | REACTOME_CELLULAR_RESPONSE_TO_HYPOXIA | 2.10e-03 | 75 | 13 | 2 | M641 | |
| Pathway | WP_ESTROGEN_SIGNALING | 2.21e-03 | 77 | 13 | 2 | MM15934 | |
| Pathway | PID_MYC_ACTIV_PATHWAY | 2.32e-03 | 79 | 13 | 2 | M66 | |
| Pathway | REACTOME_DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA | 2.50e-03 | 82 | 13 | 2 | M1002 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH4 | 2.50e-03 | 82 | 13 | 2 | M594 | |
| Pathway | PID_REG_GR_PATHWAY | 2.50e-03 | 82 | 13 | 2 | M115 | |
| Pathway | PID_SMAD2_3NUCLEAR_PATHWAY | 2.50e-03 | 82 | 13 | 2 | M2 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION | 2.62e-03 | 84 | 13 | 2 | M1008 | |
| Pathway | PID_CMYB_PATHWAY | 2.62e-03 | 84 | 13 | 2 | M195 | |
| Pathway | REACTOME_TRANSPORT_OF_SMALL_MOLECULES | 2.72e-03 | 681 | 13 | 4 | MM14985 | |
| Pathway | WP_CLEAR_CELL_RENAL_CELL_CARCINOMA_PATHWAYS | 2.75e-03 | 86 | 13 | 2 | M39375 | |
| Pathway | KEGG_TGF_BETA_SIGNALING_PATHWAY | 2.75e-03 | 86 | 13 | 2 | M2642 | |
| Pathway | KEGG_PROSTATE_CANCER | 2.94e-03 | 89 | 13 | 2 | M13191 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 27881875 | ||
| Pubmed | Expression of the nuclear coactivators CBP and p300 in developing craniofacial tissue. | 2.83e-07 | 2 | 19 | 2 | 11963968 | |
| Pubmed | Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. | 2.83e-07 | 2 | 19 | 2 | 34845315 | |
| Pubmed | p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes. | 2.83e-07 | 2 | 19 | 2 | 34813504 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 19729597 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 15860545 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 9528808 | ||
| Pubmed | Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines. | 2.83e-07 | 2 | 19 | 2 | 12696060 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 29460469 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 20301699 | ||
| Pubmed | Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer. | 2.83e-07 | 2 | 19 | 2 | 24551300 | |
| Pubmed | CBP Is Required for Establishing Adaptive Gene Programs in the Adult Mouse Brain. | 2.83e-07 | 2 | 19 | 2 | 36109165 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 24639469 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 37816914 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 12242694 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 33911074 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 9018065 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 24648406 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 30135524 | ||
| Pubmed | Binding of p300/CBP co-activators by polyoma large T antigen. | 2.83e-07 | 2 | 19 | 2 | 11438528 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 10918613 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 31182547 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 35502657 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 39287984 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 30635043 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 31898871 | ||
| Pubmed | Distribution of co-activators CBP and p300 during mouse oocyte and embryo development. | 2.83e-07 | 2 | 19 | 2 | 16596650 | |
| Pubmed | Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations. | 2.83e-07 | 2 | 19 | 2 | 27648933 | |
| Pubmed | Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity. | 2.83e-07 | 2 | 19 | 2 | 30888860 | |
| Pubmed | Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. | 2.83e-07 | 2 | 19 | 2 | 27881443 | |
| Pubmed | The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation. | 2.83e-07 | 2 | 19 | 2 | 29217654 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 19272189 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 10610021 | ||
| Pubmed | Emerging roles of p300/CBP in autophagy and autophagy-related human disorders. | 2.83e-07 | 2 | 19 | 2 | 37314181 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 20717166 | ||
| Pubmed | Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. | 2.83e-07 | 2 | 19 | 2 | 12397173 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 10049825 | ||
| Pubmed | CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding. | 2.83e-07 | 2 | 19 | 2 | 15641773 | |
| Pubmed | Differential contribution of p300 and CBP to regulatory element acetylation in mESCs. | 2.83e-07 | 2 | 19 | 2 | 32690000 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 9733868 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 30953353 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 21803292 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 9811832 | ||
| Pubmed | CBP/p300 acetyltransferase activity in hematologic malignancies. | 2.83e-07 | 2 | 19 | 2 | 27380996 | |
| Pubmed | CREBBP and p300 lysine acetyl transferases in the DNA damage response. | 2.83e-07 | 2 | 19 | 2 | 29170789 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 24089570 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 25893291 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 11559821 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 21555743 | ||
| Pubmed | Rubinstein-Taybi syndrome in Chinese population with four novel mutations. | 2.83e-07 | 2 | 19 | 2 | 33063428 | |
| Pubmed | CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells. | 2.83e-07 | 2 | 19 | 2 | 12646247 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 34506759 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 22177454 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 15706485 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 32576962 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 19822209 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 15533723 | ||
| Pubmed | AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. | 2.83e-07 | 2 | 19 | 2 | 39266679 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 36162506 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 24522976 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 22303793 | ||
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 11867645 | ||
| Pubmed | CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement. | 2.83e-07 | 2 | 19 | 2 | 21847097 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 34732714 | ||
| Pubmed | Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. | 2.83e-07 | 2 | 19 | 2 | 34019788 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 15598887 | ||
| Pubmed | Dendrite development regulated by CREST, a calcium-regulated transcriptional activator. | 8.48e-07 | 3 | 19 | 2 | 14716005 | |
| Pubmed | The acetate/ACSS2 switch regulates HIF-2 stress signaling in the tumor cell microenvironment. | 8.48e-07 | 3 | 19 | 2 | 25689462 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 18070920 | ||
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 11973335 | ||
| Pubmed | The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression. | 8.48e-07 | 3 | 19 | 2 | 21967847 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 9194564 | ||
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 15171256 | ||
| Pubmed | p300/CBP acts as a coactivator of the cone-rod homeobox transcription factor. | 8.48e-07 | 3 | 19 | 2 | 10708567 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 16428436 | ||
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 22523253 | ||
| Pubmed | Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. | 8.48e-07 | 3 | 19 | 2 | 11823864 | |
| Pubmed | CBP and p300 are essential for renin cell identity and morphological integrity of the kidney. | 8.48e-07 | 3 | 19 | 2 | 19252086 | |
| Pubmed | An essential role for p300/CBP in the cellular response to hypoxia. | 8.48e-07 | 3 | 19 | 2 | 8917528 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 19948376 | ||
| Pubmed | E2A and CBP/p300 act in synergy to promote chromatin accessibility of the immunoglobulin κ locus. | 8.48e-07 | 3 | 19 | 2 | 22544934 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 27903646 | ||
| Pubmed | Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. | 8.48e-07 | 3 | 19 | 2 | 10673499 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 12748286 | ||
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 10347196 | ||
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 10075656 | ||
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 20452968 | ||
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 24340053 | ||
| Pubmed | The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. | 8.48e-07 | 3 | 19 | 2 | 10487758 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 19166313 | ||
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 11884404 | ||
| Pubmed | HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses. | 8.48e-07 | 3 | 19 | 2 | 16001085 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 19273602 | ||
| Pubmed | p53 Transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. | 8.48e-07 | 3 | 19 | 2 | 11782467 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 23922782 | ||
| Pubmed | CREB-binding protein/p300 are transcriptional coactivators of p65. | 8.48e-07 | 3 | 19 | 2 | 9096323 | |
| Pubmed | The antibiotic drug trimethoprim suppresses tumour growth and metastasis via targeting Snail. | 8.48e-07 | 3 | 19 | 2 | 34855201 | |
| Pubmed | Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. | 8.48e-07 | 3 | 19 | 2 | 8986769 | |
| Pubmed | 8.48e-07 | 3 | 19 | 2 | 15649887 | ||
| Pubmed | Expression patterns of histone acetyltransferases p300 and CBP during murine tooth development. | 8.48e-07 | 3 | 19 | 2 | 22179676 | |
| Interaction | HOXB3 interactions | 2.70e-05 | 9 | 18 | 2 | int:HOXB3 | |
| Interaction | ARGFX interactions | 2.70e-05 | 9 | 18 | 2 | int:ARGFX | |
| Interaction | TACC2 interactions | 4.20e-05 | 77 | 18 | 3 | int:TACC2 | |
| Interaction | KLF2 interactions | 7.86e-05 | 15 | 18 | 2 | int:KLF2 | |
| Interaction | BRMS1 interactions | 8.12e-05 | 96 | 18 | 3 | int:BRMS1 | |
| Interaction | DYRK1A interactions | 9.65e-05 | 552 | 18 | 5 | int:DYRK1A | |
| Interaction | MAML2 interactions | 1.02e-04 | 17 | 18 | 2 | int:MAML2 | |
| Interaction | NEUROG1 interactions | 1.28e-04 | 19 | 18 | 2 | int:NEUROG1 | |
| Interaction | SPIB interactions | 1.42e-04 | 20 | 18 | 2 | int:SPIB | |
| Interaction | CITED4 interactions | 1.57e-04 | 21 | 18 | 2 | int:CITED4 | |
| Interaction | HOXB4 interactions | 1.57e-04 | 21 | 18 | 2 | int:HOXB4 | |
| Interaction | PLAGL1 interactions | 1.57e-04 | 21 | 18 | 2 | int:PLAGL1 | |
| Interaction | KLF13 interactions | 1.57e-04 | 21 | 18 | 2 | int:KLF13 | |
| Interaction | ZDHHC12 interactions | 1.69e-04 | 123 | 18 | 3 | int:ZDHHC12 | |
| Interaction | CITED2 interactions | 1.89e-04 | 23 | 18 | 2 | int:CITED2 | |
| Interaction | HOXD10 interactions | 1.89e-04 | 23 | 18 | 2 | int:HOXD10 | |
| Interaction | TBX21 interactions | 2.06e-04 | 24 | 18 | 2 | int:TBX21 | |
| Interaction | CNTN2 interactions | 2.06e-04 | 24 | 18 | 2 | int:CNTN2 | |
| Interaction | NR6A1 interactions | 2.06e-04 | 24 | 18 | 2 | int:NR6A1 | |
| Interaction | ALX1 interactions | 2.23e-04 | 25 | 18 | 2 | int:ALX1 | |
| Interaction | HOXB7 interactions | 2.42e-04 | 26 | 18 | 2 | int:HOXB7 | |
| Interaction | MAGEA8 interactions | 2.81e-04 | 146 | 18 | 3 | int:MAGEA8 | |
| Interaction | H4C16 interactions | 3.16e-04 | 152 | 18 | 3 | int:H4C16 | |
| Interaction | HOXD4 interactions | 3.23e-04 | 30 | 18 | 2 | int:HOXD4 | |
| Interaction | CRTC1 interactions | 3.45e-04 | 31 | 18 | 2 | int:CRTC1 | |
| Interaction | NEUROD1 interactions | 3.68e-04 | 32 | 18 | 2 | int:NEUROD1 | |
| Interaction | PIGH interactions | 3.74e-04 | 161 | 18 | 3 | int:PIGH | |
| Interaction | TRERF1 interactions | 3.91e-04 | 33 | 18 | 2 | int:TRERF1 | |
| Interaction | SLC14A1 interactions | 3.91e-04 | 33 | 18 | 2 | int:SLC14A1 | |
| Interaction | RXRA interactions | 4.31e-04 | 169 | 18 | 3 | int:RXRA | |
| Interaction | C3orf62 interactions | 4.41e-04 | 35 | 18 | 2 | int:C3orf62 | |
| Interaction | ATP11A interactions | 4.41e-04 | 35 | 18 | 2 | int:ATP11A | |
| Interaction | E2F5 interactions | 4.66e-04 | 36 | 18 | 2 | int:E2F5 | |
| Interaction | HOXB2 interactions | 4.66e-04 | 36 | 18 | 2 | int:HOXB2 | |
| Interaction | CITED1 interactions | 4.93e-04 | 37 | 18 | 2 | int:CITED1 | |
| Interaction | KLF1 interactions | 4.93e-04 | 37 | 18 | 2 | int:KLF1 | |
| Interaction | BBC3 interactions | 5.20e-04 | 38 | 18 | 2 | int:BBC3 | |
| Interaction | SERTAD2 interactions | 5.47e-04 | 39 | 18 | 2 | int:SERTAD2 | |
| Interaction | RORA interactions | 5.47e-04 | 39 | 18 | 2 | int:RORA | |
| Interaction | CCN2 interactions | 5.76e-04 | 40 | 18 | 2 | int:CCN2 | |
| Interaction | HOXB1 interactions | 6.05e-04 | 41 | 18 | 2 | int:HOXB1 | |
| Interaction | TFF1 interactions | 6.05e-04 | 41 | 18 | 2 | int:TFF1 | |
| Interaction | PROX1 interactions | 6.05e-04 | 41 | 18 | 2 | int:PROX1 | |
| Interaction | PABPN1 interactions | 6.25e-04 | 192 | 18 | 3 | int:PABPN1 | |
| Interaction | NPAS2 interactions | 6.35e-04 | 42 | 18 | 2 | int:NPAS2 | |
| Interaction | JDP2 interactions | 6.35e-04 | 42 | 18 | 2 | int:JDP2 | |
| Interaction | PRDM2 interactions | 6.66e-04 | 43 | 18 | 2 | int:PRDM2 | |
| Interaction | E2F1 interactions | 7.04e-04 | 200 | 18 | 3 | int:E2F1 | |
| Interaction | TMEM230 interactions | 7.62e-04 | 46 | 18 | 2 | int:TMEM230 | |
| Interaction | NR3C2 interactions | 7.62e-04 | 46 | 18 | 2 | int:NR3C2 | |
| Interaction | CNOT3 interactions | 7.78e-04 | 207 | 18 | 3 | int:CNOT3 | |
| Interaction | RXRG interactions | 7.95e-04 | 47 | 18 | 2 | int:RXRG | |
| Interaction | FOSB interactions | 8.64e-04 | 49 | 18 | 2 | int:FOSB | |
| Interaction | SLC34A2 interactions | 9.00e-04 | 50 | 18 | 2 | int:SLC34A2 | |
| Interaction | C1QTNF9B interactions | 9.36e-04 | 51 | 18 | 2 | int:C1QTNF9B | |
| Interaction | EID1 interactions | 9.36e-04 | 51 | 18 | 2 | int:EID1 | |
| Interaction | RARA interactions | 9.65e-04 | 223 | 18 | 3 | int:RARA | |
| Interaction | MEIS1 interactions | 9.73e-04 | 52 | 18 | 2 | int:MEIS1 | |
| Interaction | HES6 interactions | 9.73e-04 | 52 | 18 | 2 | int:HES6 | |
| Interaction | ELF3 interactions | 1.05e-03 | 54 | 18 | 2 | int:ELF3 | |
| Interaction | IRF5 interactions | 1.05e-03 | 54 | 18 | 2 | int:IRF5 | |
| Interaction | CIITA interactions | 1.09e-03 | 55 | 18 | 2 | int:CIITA | |
| Interaction | BCL3 interactions | 1.13e-03 | 56 | 18 | 2 | int:BCL3 | |
| Interaction | LDB2 interactions | 1.13e-03 | 56 | 18 | 2 | int:LDB2 | |
| Interaction | SMAD1 interactions | 1.24e-03 | 243 | 18 | 3 | int:SMAD1 | |
| Interaction | HOXB6 interactions | 1.29e-03 | 60 | 18 | 2 | int:HOXB6 | |
| Interaction | MAF interactions | 1.29e-03 | 60 | 18 | 2 | int:MAF | |
| Interaction | ETS2 interactions | 1.34e-03 | 61 | 18 | 2 | int:ETS2 | |
| Interaction | CEBPD interactions | 1.38e-03 | 62 | 18 | 2 | int:CEBPD | |
| Interaction | HOXA10 interactions | 1.38e-03 | 62 | 18 | 2 | int:HOXA10 | |
| Interaction | RBPJ interactions | 1.40e-03 | 254 | 18 | 3 | int:RBPJ | |
| Interaction | DEAF1 interactions | 1.47e-03 | 64 | 18 | 2 | int:DEAF1 | |
| Interaction | PAX5 interactions | 1.47e-03 | 64 | 18 | 2 | int:PAX5 | |
| Interaction | NFYB interactions | 1.52e-03 | 65 | 18 | 2 | int:NFYB | |
| Interaction | NKAIN1 interactions | 1.52e-03 | 65 | 18 | 2 | int:NKAIN1 | |
| GeneFamily | Proprotein convertase subtilisin/kexin family | 1.45e-05 | 9 | 12 | 2 | 973 | |
| GeneFamily | ATPase phospholipid transporting | 4.22e-05 | 15 | 12 | 2 | 1210 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 5.46e-05 | 17 | 12 | 2 | 486 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 6.14e-05 | 18 | 12 | 2 | 91 | |
| ToppCell | AT2_cells-SSc-ILD_01|World / lung cells shred on cell class, cell subclass, sample id | 1.04e-06 | 197 | 18 | 4 | 42e49a8ce3118db6c2fd620d70c480b75143c828 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Myeloid-myeloid_leukocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.34e-05 | 158 | 18 | 3 | 91d265e95156f16459924d3e4dd11c180e164eee | |
| ToppCell | 367C-Epithelial_cells-Epithelial-A_(AT2)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 3.73e-05 | 164 | 18 | 3 | b0ed8cb6000ce8bf94444307e4b7b3574fa3fab2 | |
| ToppCell | 367C-Epithelial_cells-Epithelial-A_(AT2)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 3.73e-05 | 164 | 18 | 3 | 3aea6207a011ad55a1aeb2ed9fb54d31b23694b5 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.73e-05 | 164 | 18 | 3 | b6df1e67a5ce5f2d86f4e1420f4ee931f760bf4d | |
| ToppCell | AT2_cells-Myositis-ILD_01|World / lung cells shred on cell class, cell subclass, sample id | 5.00e-05 | 181 | 18 | 3 | ed0ea67f0607073aedf153f8d1073b35e46127c3 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Hematopoietic-Megakaryocytic-Megakaryocyte|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.00e-05 | 181 | 18 | 3 | c5843b89f3d362e236ff76c3279518a2fdfc1f75 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Hematopoietic-Megakaryocytic|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.00e-05 | 181 | 18 | 3 | 14c2dd946e89ba578711c2d25935b6b3d319b701 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Hematopoietic-Megakaryocytic-Megakaryocyte-Mega|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.00e-05 | 181 | 18 | 3 | fcefb5902416c004631f4f8dd5c8f99fe3bd90bc | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Hematopoietic|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.00e-05 | 181 | 18 | 3 | 9dc0563453e24c9d1d975e2e0e1e272487e19908 | |
| ToppCell | 367C-Epithelial_cells-Epithelial-A_(AT2)-|367C / Donor, Lineage, Cell class and subclass (all cells) | 5.25e-05 | 184 | 18 | 3 | 2a8338e94937686a148b5433515700ca0f674058 | |
| ToppCell | 367C-Epithelial_cells-Epithelial-A_(AT2)|367C / Donor, Lineage, Cell class and subclass (all cells) | 5.25e-05 | 184 | 18 | 3 | 0ba243cbf69b4fe6ae100a7f0314317bec38026c | |
| ToppCell | AT2_cells-IPF_01|World / lung cells shred on cell class, cell subclass, sample id | 5.33e-05 | 185 | 18 | 3 | 3b3268e3f99121124e33086cac88479808d31630 | |
| ToppCell | 367C-Epithelial_cells-Epithelial-E_(AT2)|367C / Donor, Lineage, Cell class and subclass (all cells) | 5.51e-05 | 187 | 18 | 3 | 0277d4e54bd4d48f30241c2951a569209423fee8 | |
| ToppCell | 367C-Epithelial_cells-Epithelial-E_(AT2)-|367C / Donor, Lineage, Cell class and subclass (all cells) | 5.51e-05 | 187 | 18 | 3 | 11670a85db87cbb3e78022a589632173604b0940 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.1.3|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.51e-05 | 187 | 18 | 3 | 7c44cec1c26ca5907a495f2d7e633410e2e9728f | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.68e-05 | 189 | 18 | 3 | da014519d6eb21bc2dc2ed65eafe638b42a068ed | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.68e-05 | 189 | 18 | 3 | e90ba6f6d7ba0698d04d84278aa035c28803733e | |
| ToppCell | COVID-19-lung-AT2|COVID-19 / Disease (COVID-19 only), tissue and cell type | 5.77e-05 | 190 | 18 | 3 | 27a1a86620fe9b5ee930d388b32352206485e6d0 | |
| ToppCell | COVID-19-lung-AT2|lung / Disease (COVID-19 only), tissue and cell type | 5.86e-05 | 191 | 18 | 3 | 276455a64c2c3503d5048615762eb2ee37f0ac70 | |
| ToppCell | (7)_Epithelial-E_(AT2)|World / Lung cell shreds - cell class (v4) and cell subclass (v4) | 5.86e-05 | 191 | 18 | 3 | 0fc8d109d5c50957ceef5b8b8b818b0c598b1bbe | |
| ToppCell | AT2|World / shred by cell class for parenchyma | 6.14e-05 | 194 | 18 | 3 | e773f5ef3abce7113a6b7cc7cbe68de873d4a17f | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.0.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.14e-05 | 194 | 18 | 3 | 0db439a544cf8f918a77058fd70319ab0e8e645e | |
| ToppCell | (7)_Epithelial_cells|World / Lung cell shreds - cell class (v4) and cell subclass (v4) | 6.14e-05 | 194 | 18 | 3 | 413e8b9f1e15be363a7f4a8f727af3eeb9e9a928 | |
| ToppCell | normal_Lung-Epithelial_cells-AT2|Epithelial_cells / Location, Cell class and cell subclass | 6.24e-05 | 195 | 18 | 3 | 81e13fe337f1d0a83d0deb86a0df797d306cd24d | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.0.3|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.24e-05 | 195 | 18 | 3 | 37aa6e4123d37de4de42ca68d3020f2a7686ce02 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.33e-05 | 196 | 18 | 3 | 7e5addaa844e66f8160e05858c341866a80aed23 | |
| ToppCell | 10x5'v1-week_12-13-Hematopoietic-erythroid|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.33e-05 | 196 | 18 | 3 | 0aae78e73d53416d857bdf21f595a0a0a0ba7944 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Alveolar_epithelium|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.33e-05 | 196 | 18 | 3 | 69f27c2668a9f412b2eb6ca83d11b44863209542 | |
| ToppCell | 3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.43e-05 | 197 | 18 | 3 | bf10727fbe90b71d2ac60a11711e5f0701b3799d | |
| ToppCell | 356C-Epithelial_cells-Epithelial-B_(AT2)-|356C / Donor, Lineage, Cell class and subclass (all cells) | 6.43e-05 | 197 | 18 | 3 | 06ed8f293d4ee89f14dc2f43d6cae93bbc02508a | |
| ToppCell | 356C-Epithelial_cells-Epithelial-B_(AT2)|356C / Donor, Lineage, Cell class and subclass (all cells) | 6.43e-05 | 197 | 18 | 3 | c115d0a45545ed24259ad88872231bf4d4d389d2 | |
| ToppCell | AT2_cells-HP_01|World / lung cells shred on cell class, cell subclass, sample id | 6.43e-05 | 197 | 18 | 3 | 8b5d4e1c33a57c899c51feb9a6f347232f8910a3 | |
| ToppCell | 367C-Epithelial_cells-Epithelial-E_(AT2)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.52e-05 | 198 | 18 | 3 | 85215015bb86ada0e871c413a4ecdc903a3785ca | |
| ToppCell | distal-1-Epithelial-Alveolar_Epithelial_Type_2|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 6.52e-05 | 198 | 18 | 3 | ce9d6b2a93c7b304414ce1b8b1a09562cf581278 | |
| ToppCell | 367C-Epithelial_cells-Epithelial-E_(AT2)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.52e-05 | 198 | 18 | 3 | 38349e42a3f1fb700ff6dfd89c4bf5ff97f1a3e9 | |
| ToppCell | Parenchymal-10x3prime_v2-Epithelial-Epi_alveolar|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 6.62e-05 | 199 | 18 | 3 | 7ebd89dff457f57a549eecee288c7a4b515b4018 | |
| ToppCell | Biopsy_Other_PF-Epithelial-AT2|Biopsy_Other_PF / Sample group, Lineage and Cell type | 6.62e-05 | 199 | 18 | 3 | 9a65acfe9bf500db72142469cf17bf0973540001 | |
| ToppCell | Parenchymal-10x3prime_v2-Epithelial-Epi_alveolar-AT2|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 6.62e-05 | 199 | 18 | 3 | fa5ddba3ac1ebe712cd4cdc3f20339f7c715d039 | |
| ToppCell | Biopsy_IPF-Epithelial-AT2|Biopsy_IPF / Sample group, Lineage and Cell type | 6.62e-05 | 199 | 18 | 3 | c841d475703d3489161fb7904526bd7563d5fb0f | |
| ToppCell | Tracheal-10x3prime_v2-Immune_Myeloid-Macrophage_other-Macrophage_intermediate|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 3.39e-04 | 68 | 18 | 2 | f1cbc6d72489272c1eb6200f64b8b6444719acda | |
| ToppCell | Striatum-Macroglia-POLYDENDROCYTE-P5-P5_2-Sox4-POLYDENDROCYTE_(Rostral-�migratory_stream-�(RMS)_(Notum))|Striatum / BrainAtlas - Mouse McCarroll V32 | 3.91e-04 | 73 | 18 | 2 | 50a8164d967f2706344adcdc1562dc08c9f16c8f | |
| ToppCell | 367C-Epithelial_cells-Epithelial-B_(AT2)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.88e-04 | 97 | 18 | 2 | eab10b1af9cd0ce373cd4d0316e0d7b218630584 | |
| ToppCell | 367C-Epithelial_cells-Epithelial-B_(AT2)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.88e-04 | 97 | 18 | 2 | 04f571708f2487b0dbd70ee507de6bf75be5f5d9 | |
| ToppCell | LA-12._Cytoplasmic_Cardiomyocyte_II|LA / Chamber and Cluster_Paper | 7.75e-04 | 103 | 18 | 2 | e457f25e65a62c94685b15cd73fd3278fb94bf9c | |
| ToppCell | control-Myeloid-Monocyte-derived_DC|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 8.52e-04 | 108 | 18 | 2 | e74e73d89d78c8d59dfdd2bd30db54b366a49d23 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_1-Sox4-POLYDENDROCYTE_(Neurogenesis.Sox4.Hist1h2al)|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.16e-03 | 126 | 18 | 2 | 6072996987f7b05949adb86c9433e3302c4441d2 | |
| ToppCell | NS-control-d_0-4-Myeloid-Monocyte-derived_DC|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.17e-03 | 127 | 18 | 2 | 1f9039d2a9e418c41716c3608d4d03574b71904a | |
| ToppCell | control-Myeloid-Monocyte-derived_DC|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 1.19e-03 | 128 | 18 | 2 | 4a1f7b76b64df06531db79e427eda084374ce7b5 | |
| ToppCell | Frontal_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.21e-03 | 129 | 18 | 2 | 856255fbfc7f95642000cfd7704141b2388f7c5c | |
| ToppCell | Substantia_nigra-Endothelial-ENDOTHELIAL_STALK|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 1.25e-03 | 131 | 18 | 2 | 308ddb7fe113eac5dbeb9cb0b688d9e09275ce5e | |
| ToppCell | Substantia_nigra-Endothelial-ENDOTHELIAL_STALK-Flt1_1|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 1.27e-03 | 132 | 18 | 2 | 06e7337de35bd7120655a22b6020604ad004c4e1 | |
| ToppCell | Hippocampus-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.31e-03 | 134 | 18 | 2 | b959899c89d3a0363a3cd2309155280e0fe5ba88 | |
| ToppCell | Mild/Remission-B_intermediate-10|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.34e-03 | 136 | 18 | 2 | 1b3c6edcbe0eb674d2d9c838e83ebe2b93e3eec1 | |
| ToppCell | MS-CD4-CD4_Treg|MS / Condition, Cell_class and T cell subcluster | 1.44e-03 | 141 | 18 | 2 | df257dd4dcc45c1ace57340798e150a6e932531d | |
| ToppCell | Mild/Remission-B_naive-13|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.46e-03 | 142 | 18 | 2 | 49873a2d9b1ae4bdbf253d1c09bf8845cc0cc917 | |
| ToppCell | Megakaryocytic-erythropoietic-Erythro-cells-Erythrocyte|Erythro-cells / Lineage, cell class and subclass | 1.51e-03 | 144 | 18 | 2 | 7fbedc65314cfb06bcc527d794b5de7858f7c5ec | |
| ToppCell | Globus_pallidus-Endothelial-ENDOTHELIAL_STALK-Flt1_1|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 1.51e-03 | 144 | 18 | 2 | 1c118b22c2ff3a526a5207d6c9d772636ee065fd | |
| ToppCell | Mild/Remission-B_naive-13|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.53e-03 | 145 | 18 | 2 | 7827aef87f834cd0d19780417757c9386e19b22e | |
| ToppCell | COVID-19_Moderate-multiplets|COVID-19_Moderate / disease group, cell group and cell class | 1.57e-03 | 147 | 18 | 2 | baf15c773d7751bc6f64d4974a22738626f2b3ff | |
| ToppCell | COVID-19-kidney-Lymphatic_EC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.59e-03 | 148 | 18 | 2 | f777aa1674e898e2594b2b7c029d3d05dda04df9 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_1|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.59e-03 | 148 | 18 | 2 | b9d3421c2eb8e748e9508c1cbd1cb4f96e23db5a | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_1-Sox4|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.59e-03 | 148 | 18 | 2 | 2a7671dc27afbdf6a92d976c5f2b728bd18dd609 | |
| ToppCell | Globus_pallidus-Endothelial-ENDOTHELIAL_STALK|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 1.61e-03 | 149 | 18 | 2 | d9c47f523c75ddcd6131e45d2ffc24b970932cae | |
| ToppCell | 3'_v3-bone_marrow-Lymphocytic_Invariant-Inducer-like-ILC3|bone_marrow / Manually curated celltypes from each tissue | 1.61e-03 | 149 | 18 | 2 | d7f1069f70f3cad6d3700ee2041ed1d4cb7c49ab | |
| ToppCell | facs-Brain_Non-Myeloid-Hippocampus-24m-Macroglial-oligodendrocyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.63e-03 | 150 | 18 | 2 | afd651c654e715414eff64cf3a37378d057a56a2 | |
| ToppCell | Healthy_donor-RBC|World / disease group, cell group and cell class (v2) | 1.63e-03 | 150 | 18 | 2 | 1e1a497ec4b048f7e9cc12dd5dd9aba7fedca9e1 | |
| ToppCell | P03-Epithelial-epithelial_progenitor_cell-epi_progenitor|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.65e-03 | 151 | 18 | 2 | fce04bce66411c21cd5d4d41375f26f1f50f3348 | |
| ToppCell | Frontal_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.72e-03 | 154 | 18 | 2 | 65dbb60f636562eeba3dafadae9c0c7db2b27476 | |
| ToppCell | Healthy_donor-RBC|Healthy_donor / disease group, cell group and cell class (v2) | 1.72e-03 | 154 | 18 | 2 | e080d5104fe6f3f6ef617bbcdccf1332ab7231e1 | |
| ToppCell | mild_COVID-19_(asymptomatic)-CD8+_T_naive|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2) | 1.74e-03 | 155 | 18 | 2 | e2c901d5c9e42d25d7702e5e8fc19b06f7c817be | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Dendritic-conventional_dendritic_cell-DC_c1-CLEC9A|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.74e-03 | 155 | 18 | 2 | d76a0f99ec35560d18820f9c92b69364ef2250e3 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-high_Fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.74e-03 | 155 | 18 | 2 | 82e602f31981c6b48abff2a04b2ab5d26d4462a2 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-high_Fibroblast-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.74e-03 | 155 | 18 | 2 | 979c1d53b435a82c57d16707eed8ba7346326866 | |
| ToppCell | COVID-19_Moderate-multiplets|World / disease group, cell group and cell class | 1.76e-03 | 156 | 18 | 2 | afdc025fa75e7926b1cc182c4a33654a2186abb1 | |
| ToppCell | NS-moderate-d_07-13-Epithelial-FOXN4+|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.78e-03 | 157 | 18 | 2 | 410c9d74a2085179cfb39853cb6d330fa98c9c1b | |
| ToppCell | frontal_cortex-Non-neuronal-leptomeningeal_cell-VLMC-VLMC_Spp1_Col15a1|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.83e-03 | 159 | 18 | 2 | 34c90711c5857cf6ada7b3acff99f1d48c7caf29 | |
| ToppCell | 18-Airway-Epithelial-Bud_tip_progenitor|Airway / Age, Tissue, Lineage and Cell class | 1.83e-03 | 159 | 18 | 2 | e715cadff8e7d5ebe4c2198dbdfd3ca41ecb8a6a | |
| ToppCell | Hippocampus-Endothelial-ENDOTHELIAL_TIP-Dcn_1|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 1.83e-03 | 159 | 18 | 2 | 92049a8d8fc9997d8d0d76500c72596a9b2394e0 | |
| ToppCell | 356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1.5|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 1.85e-03 | 160 | 18 | 2 | 8bb873704895c3b35bba8af78fedbabf7df42e71 | |
| ToppCell | droplet-Liver-HEPATOCYTES-1m-Epithelial-Hepatocyte_(Pericentral)|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.85e-03 | 160 | 18 | 2 | c42bcc6c7d113f0db43febb088b75ca4ac7cb7a3 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.88e-03 | 161 | 18 | 2 | 1b805f77790aeb8a71b08bfac2fe2eed7343258f | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Myeloid-macrophage/monocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.90e-03 | 162 | 18 | 2 | 93bd29c52846c3156b8b0d2e39c552373efdfe93 | |
| ToppCell | P07-Endothelial-lymphatic_endothelial_cell|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.92e-03 | 163 | 18 | 2 | 5cbab3d03bb1af9391ecad635d6eea1dd42c1337 | |
| ToppCell | P07-Endothelial-lymphatic_endothelial_cell-endothelial_cell_of_lymphatic_vessel|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.92e-03 | 163 | 18 | 2 | 322ba94c3ec1e1859c2e2195ecb3f7dab8d190f6 | |
| ToppCell | PND03-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.92e-03 | 163 | 18 | 2 | 7864e966c228282b4b63c43164dba3faba21026d | |
| ToppCell | 343B-Epithelial_cells-Epithelial-A_(AT2)-|343B / Donor, Lineage, Cell class and subclass (all cells) | 1.94e-03 | 164 | 18 | 2 | beaa13a75c3bb72446c85084d75e9fe3f15fd3d4 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-A_(AT2)|343B / Donor, Lineage, Cell class and subclass (all cells) | 1.94e-03 | 164 | 18 | 2 | d005cfd821b87548b075120bffe65a0be9860463 | |
| ToppCell | PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_prolif|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.99e-03 | 166 | 18 | 2 | 575c325db88d6909cdf0d5e664bd9098b89d4401 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-D-|356C / Donor, Lineage, Cell class and subclass (all cells) | 1.99e-03 | 166 | 18 | 2 | 7c2eee0a4f45795a956acf936b85bdb35f1b1624 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-D|356C / Donor, Lineage, Cell class and subclass (all cells) | 1.99e-03 | 166 | 18 | 2 | 7286a37b2827f3747469ffd0d76cbe81116db7ee | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-myocytic-myofibroblast_(RSPO2+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.02e-03 | 167 | 18 | 2 | b742558ca92985db0a67c88f530bc375f3d3bb98 | |
| ToppCell | droplet-Kidney-nan-18m-Epithelial-Epcam____brush_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.02e-03 | 167 | 18 | 2 | ed7e785dcd25777f64e0c2596ada4f5a5ea17121 | |
| ToppCell | facs-Aorta-Heart-24m-Endothelial-endocardial_endothelial_cells|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.04e-03 | 168 | 18 | 2 | edbab94f14e16a1a76546a18fe777a183080d1de | |
| ToppCell | Hippocampus-Endothelial-ENDOTHELIAL_TIP|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 2.04e-03 | 168 | 18 | 2 | 26aa96b2b547d11941cb803995ea3d302ee0518c | |
| ToppCell | frontal_cortex-Non-neuronal-leptomeningeal_cell-VLMC-VLMC_Osr1_Mc5r|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 2.04e-03 | 168 | 18 | 2 | 9930bd63b60c03f0152838a79eef77da1c2dd8e5 | |
| ToppCell | Mild/Remission-B_naive-4|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 2.06e-03 | 169 | 18 | 2 | c3a6179a64589a370108fea809b157839347759c | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Immune-Myeloid-Macrophage_Dendritic-Cycling_Mononuclear_Phagocyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.06e-03 | 169 | 18 | 2 | 54b13ab02b4c187f4754045ecfcf409749e7ccc0 | |
| ToppCell | droplet-Kidney-nan-18m-Epithelial-brush_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.06e-03 | 169 | 18 | 2 | f00741203efa0b948db7223ee8c19bdd0918258a | |
| ToppCell | NS-critical-LOC-Epithelial-FOXN4+|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.09e-03 | 170 | 18 | 2 | f6a0162bb690dbc19ff1cec64cb933744ad3b496 | |
| Drug | Karakoline [39089-30-0]; Down 200; 10.6uM; MCF7; HT_HG-U133A | 3.43e-07 | 195 | 18 | 5 | 6059_DN | |
| Drug | 3,4-dimethoxy-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenylbenzenesulfonamide | 5.89e-06 | 5 | 18 | 2 | ctd:C575894 | |
| Drug | Cyclosporin A [59865-13-3]; Down 200; 3.4uM; MCF7; HT_HG-U133A | 1.42e-05 | 194 | 18 | 4 | 4411_DN | |
| Drug | felodipine; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 1.48e-05 | 196 | 18 | 4 | 848_DN | |
| Drug | Isosorbide dinitrate [87-33-2]; Down 200; 17uM; HL60; HT_HG-U133A | 1.48e-05 | 196 | 18 | 4 | 2183_DN | |
| Drug | Methoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; MCF7; HT_HG-U133A | 1.48e-05 | 196 | 18 | 4 | 3302_DN | |
| Drug | Rauwolscine hydrochloride [6211-32-1]; Up 200; 10.2uM; MCF7; HT_HG-U133A | 1.48e-05 | 196 | 18 | 4 | 2778_UP | |
| Drug | Alprenolol hydrochloride [13707-88-5]; Up 200; 14uM; MCF7; HT_HG-U133A | 1.51e-05 | 197 | 18 | 4 | 3188_UP | |
| Drug | Eserine sulfate, physostigmine sulfate [64-47-1]; Up 200; 6.2uM; MCF7; HT_HG-U133A | 1.54e-05 | 198 | 18 | 4 | 2768_UP | |
| Drug | Trimethobenzamide hydrochloride [554-92-7]; Up 200; 9.4uM; MCF7; HT_HG-U133A | 1.54e-05 | 198 | 18 | 4 | 1502_UP | |
| Drug | Iobenguane sulfate; Down 200; 10.8uM; MCF7; HT_HG-U133A | 1.57e-05 | 199 | 18 | 4 | 2878_DN | |
| Drug | troglitazone | 4.09e-05 | 1329 | 18 | 7 | ctd:C057693 | |
| Drug | 4,4'-DBP | 1.00e-04 | 19 | 18 | 2 | CID000007034 | |
| Drug | Arginylarginine | 2.72e-04 | 163 | 18 | 3 | CID000151956 | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 3.13e-04 | 171 | 18 | 3 | 6879_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 3.23e-04 | 173 | 18 | 3 | 2881_DN | |
| Drug | Ethaverine hydrochloride [985-13-7]; Down 200; 9.2uM; HL60; HT_HG-U133A | 3.29e-04 | 174 | 18 | 3 | 3037_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 3.57e-04 | 179 | 18 | 3 | 5822_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A | 3.63e-04 | 180 | 18 | 3 | 6886_DN | |
| Drug | Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A | 3.63e-04 | 180 | 18 | 3 | 4541_DN | |
| Drug | 17-AAG; Up 200; 1uM; PC3; HT_HG-U133A | 4.06e-04 | 187 | 18 | 3 | 5958_UP | |
| Drug | GW8510; Down 200; 10uM; MCF7; HT_HG-U133A | 4.06e-04 | 187 | 18 | 3 | 7080_DN | |
| Drug | Chlorambucil [305-03-3]; Down 200; 13.2uM; PC3; HT_HG-U133A | 4.19e-04 | 189 | 18 | 3 | 3788_DN | |
| Drug | Cyclosporin A [59865-13-3]; Up 200; 3.4uM; HL60; HT_HG-U133A | 4.19e-04 | 189 | 18 | 3 | 1331_UP | |
| Drug | Methoxy-6-harmalan [3589-73-9]; Up 200; 18.6uM; MCF7; HT_HG-U133A | 4.19e-04 | 189 | 18 | 3 | 5455_UP | |
| Drug | Benzethonium chloride [121-54-0]; Down 200; 9uM; HL60; HT_HG-U133A | 4.19e-04 | 189 | 18 | 3 | 2508_DN | |
| Drug | Mianserine hydrochloride [21535-47-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A | 4.19e-04 | 189 | 18 | 3 | 2231_UP | |
| Drug | PNU-0230031 [267429-39-0]; Up 200; 10uM; MCF7; HT_HG-U133A | 4.26e-04 | 190 | 18 | 3 | 3629_UP | |
| Drug | Ellipticine [519-23-3]; Up 200; 16.2uM; MCF7; HT_HG-U133A | 4.26e-04 | 190 | 18 | 3 | 6253_UP | |
| Drug | Disulfiram [97-77-8]; Up 200; 13.4uM; PC3; HT_HG-U133A | 4.32e-04 | 191 | 18 | 3 | 5729_UP | |
| Drug | 17-AAG; Down 200; 1uM; HL60; HT_HG-U133A | 4.32e-04 | 191 | 18 | 3 | 2685_DN | |
| Drug | Ricinine [524-40-3]; Down 200; 24.4uM; HL60; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 2505_DN | |
| Drug | Cimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 1464_DN | |
| Drug | Fenbufen [36330-85-5]; Up 200; 15.8uM; HL60; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 2346_UP | |
| Drug | Calycanthine [595-05-1]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 2764_UP | |
| Drug | Remoxipride Hydrochloride [73220-03-8]; Down 200; 9.8uM; HL60; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 3124_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A | 4.46e-04 | 193 | 18 | 3 | 2721_DN | |
| Drug | Glycocholic acid [475-31-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 5316_DN | |
| Drug | Tetrandrine [518-34-3]; Down 200; 6.4uM; HL60; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 2520_DN | |
| Drug | Proglumide [6620-60-6]; Down 200; 12uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 3861_DN | |
| Drug | Picrotoxinin [17617-45-7]; Up 200; 13.6uM; PC3; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 4260_UP | |
| Drug | Alsterpaullone; Up 200; 10uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 7051_UP | |
| Drug | Fenspiride hydrochloride [5053-08-7]; Up 200; 13.4uM; HL60; HG-U133A | 4.52e-04 | 194 | 18 | 3 | 1422_UP | |
| Drug | Cinchonine [118-10-5]; Up 200; 13.6uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 2789_UP | |
| Drug | Acetylsalicylsalicylic acid [530-75-6]; Down 200; 13.4uM; HL60; HG-U133A | 4.52e-04 | 194 | 18 | 3 | 1377_DN | |
| Drug | Ranitidine hydrochloride [66357-59-3]; Up 200; 11.4uM; HL60; HG-U133A | 4.52e-04 | 194 | 18 | 3 | 1404_UP | |
| Drug | semustine; Up 200; 100uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 7487_UP | |
| Drug | Piperacillin sodium salt [59703-84-3]; Down 200; 7.4uM; PC3; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 4320_DN | |
| Drug | Skimmianine [83-95-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 6242_UP | |
| Drug | Oxyphenbutazone [129-20-4]; Down 200; 12.4uM; HL60; HT_HG-U133A | 4.52e-04 | 194 | 18 | 3 | 6160_DN | |
| Drug | Ebselen [60940-34-3]; Down 200; 14.6uM; MCF7; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 3458_DN | |
| Drug | Xylazine [7361-61-7]; Up 200; 18.2uM; HL60; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 2132_UP | |
| Drug | 5279552; Down 200; 22uM; MCF7; HT_HG-U133A_EA | 4.59e-04 | 195 | 18 | 3 | 843_DN | |
| Drug | Deoxycorticosterone [64-85-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 5357_DN | |
| Drug | Clomiphene citrate (Z,E) [50-41-9]; Up 200; 6.6uM; MCF7; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 2624_UP | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 2208_DN | |
| Drug | Ethamsylate [2624-44-4]; Down 200; 15.2uM; MCF7; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 4399_DN | |
| Drug | Ethopropazine hydrochloride [1094-08-2]; Down 200; 11.4uM; MCF7; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 3376_DN | |
| Drug | Flutamide [13311-84-7]; Down 200; 14.4uM; HL60; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 2358_DN | |
| Drug | Tetrandrine [518-34-3]; Down 200; 6.4uM; MCF7; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 6082_DN | |
| Drug | Pyrithyldione [77-04-3]; Down 200; 24uM; HL60; HT_HG-U133A | 4.59e-04 | 195 | 18 | 3 | 2740_DN | |
| Drug | Clorsulon [60200-06-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 7025_UP | |
| Drug | Cephalexin monohydrate [23325-78-2]; Up 200; 11uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2628_UP | |
| Drug | LY 294002; Down 200; 10uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2687_DN | |
| Drug | Trimetazidine dihydrochloride [13171-25-0]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2876_UP | |
| Drug | Paclitaxel [33069-62-4]; Up 200; 4.6uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 5320_UP | |
| Drug | Oxolinic acid [14698-29-4]; Down 200; 15.4uM; PC3; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2103_DN | |
| Drug | Methylergometrine maleate [113-42-8]; Down 200; 8.8uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 3222_DN | |
| Drug | Harpagoside [19210-12-9]; Down 200; 8uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2935_DN | |
| Drug | Roxarsone [121-19-7]; Up 200; 15.2uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2950_UP | |
| Drug | Chlorpromazine hydrochloride [69-09-0]; Down 200; 11.2uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 1864_DN | |
| Drug | Thiamine hydrochloride [67-03-8]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 7479_UP | |
| Drug | Metyrapone [54-36-4]; Up 200; 17.6uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 3070_UP | |
| Drug | Acyclovir [59277-89-3]; Up 200; 17.8uM; PC3; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 4683_UP | |
| Drug | CP-690334-01 [459212-38-5]; Up 200; 1uM; PC3; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 3826_UP | |
| Drug | Proparacaine hydrochloride [5875-06-9]; Down 200; 12uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 3113_DN | |
| Drug | Adamantamine fumarate [80789-67-9]; Up 200; 9.6uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 1344_UP | |
| Drug | ICI182,780; Down 200; 1uM; PC3; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 7495_DN | |
| Drug | Betonicine [515-25-3]; Down 200; 25.2uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2207_DN | |
| Drug | Fluvoxamine maleate [61718-82-9]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 7333_DN | |
| Drug | Gemfibrozil [25812-30-0]; Up 200; 16uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2277_UP | |
| Drug | Hydroxytacrine maleate (R,S) [118909-22-1]; Up 200; 12.2uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 2430_UP | |
| Drug | Adiphenine hydrochloride [50-42-0]; Up 200; 11.4uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 1872_UP | |
| Drug | daunorubicin HCl; Up 200; 1uM; PC3; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 7511_UP | |
| Drug | Florfenicol [73231-34-2]; Up 200; 11.2uM; HL60; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 3083_UP | |
| Drug | Phenylpropanolamine hydrochloride [154-41-6]; Up 200; 21.4uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 5298_UP | |
| Drug | Spironolactone [52-01-7]; Up 200; 9.6uM; PC3; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 5781_UP | |
| Drug | Lincomycin hydrochloride [859-18-7]; Down 200; 9uM; MCF7; HT_HG-U133A | 4.66e-04 | 196 | 18 | 3 | 7411_DN | |
| Drug | Flumequine [42835-25-6]; Up 200; 15.4uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 2276_UP | |
| Drug | Cefazolin sodium salt [27164-46-1]; Up 200; 8.4uM; HL60; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 2564_UP | |
| Drug | Sulfamethizole [144-82-1]; Down 200; 14.8uM; HL60; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 2536_DN | |
| Drug | Amidopyrine [58-15-1]; Up 200; 17.2uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 2222_UP | |
| Drug | Epitiostanol [2363-58-8]; Down 200; 13uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 7342_DN | |
| Drug | Esculetin [305-01-1]; Up 200; 22.4uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 7459_UP | |
| Drug | 0316684-0000 [391209-55-5]; Up 200; 10uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 7052_UP | |
| Drug | prochlorperazine dimaleate salt; Down 200; 10uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 1640_DN | |
| Drug | Propoxycaine hydrochloride [550-83-4]; Up 200; 12uM; HL60; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 6161_UP | |
| Drug | Meclocycline sulfosalicylate [73816-42-9]; Down 200; 5.8uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 3277_DN | |
| Drug | 17-DMAG; Down 200; 0.1uM; HL60; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 1154_DN | |
| Drug | Ajmalicine hydrochloride [4373-34-6]; Up 200; 10.2uM; MCF7; HT_HG-U133A | 4.73e-04 | 197 | 18 | 3 | 2898_UP | |
| Disease | RUBINSTEIN-TAYBI SYNDROME 1 | 3.51e-07 | 2 | 18 | 2 | C4551859 | |
| Disease | Menke-Hennekam syndrome | 3.51e-07 | 2 | 18 | 2 | cv:C5681632 | |
| Disease | Rubinstein-Taybi syndrome (is_implicated_in) | 3.51e-07 | 2 | 18 | 2 | DOID:1933 (is_implicated_in) | |
| Disease | Rubinstein-Taybi syndrome (implicated_via_orthology) | 3.51e-07 | 2 | 18 | 2 | DOID:1933 (implicated_via_orthology) | |
| Disease | RUBINSTEIN-TAYBI SYNDROME 1 | 3.51e-07 | 2 | 18 | 2 | 180849 | |
| Disease | Rubinstein-Taybi syndrome due to CREBBP mutations | 3.51e-07 | 2 | 18 | 2 | cv:C4551859 | |
| Disease | Rubinstein-Taybi syndrome | 3.51e-07 | 2 | 18 | 2 | cv:C0035934 | |
| Disease | Rubinstein-Taybi Syndrome | 3.51e-07 | 2 | 18 | 2 | C0035934 | |
| Disease | Bladder Neoplasm | 8.10e-05 | 140 | 18 | 3 | C0005695 | |
| Disease | Malignant neoplasm of urinary bladder | 8.27e-05 | 141 | 18 | 3 | C0005684 | |
| Disease | Carcinoma, Transitional Cell | 2.84e-04 | 41 | 18 | 2 | C0007138 | |
| Disease | Small cell carcinoma of lung | 4.94e-04 | 54 | 18 | 2 | C0149925 | |
| Disease | Diffuse Large B-Cell Lymphoma | 5.12e-04 | 55 | 18 | 2 | C0079744 | |
| Disease | Precursor Cell Lymphoblastic Leukemia Lymphoma | 6.30e-04 | 61 | 18 | 2 | C1961102 | |
| Disease | Squamous cell carcinoma of esophagus | 1.52e-03 | 95 | 18 | 2 | C0279626 | |
| Disease | Adenoid Cystic Carcinoma | 1.68e-03 | 100 | 18 | 2 | C0010606 | |
| Disease | Squamous cell carcinoma | 2.56e-03 | 124 | 18 | 2 | C0007137 | |
| Disease | Leukemia, Myelocytic, Acute | 4.92e-03 | 173 | 18 | 2 | C0023467 | |
| Disease | alcohol use disorder (implicated_via_orthology) | 6.20e-03 | 195 | 18 | 2 | DOID:1574 (implicated_via_orthology) | |
| Disease | Adenocarcinoma of lung (disorder) | 6.89e-03 | 206 | 18 | 2 | C0152013 | |
| Disease | obsolete_red blood cell distribution width | 7.92e-03 | 1347 | 18 | 4 | EFO_0005192 | |
| Disease | melanoma | 9.85e-03 | 248 | 18 | 2 | C0025202 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| YQEPWQYVDDIWLMF | 1111 | Q09472 | |
| NMQYIPREDFPDWWQ | 231 | P51813 | |
| QYQEPWQYVDDVWLM | 1146 | Q92793 | |
| PWIMQDYNYPVEWQS | 261 | Q14680 | |
| EKMAYQEYPNSQNWP | 106 | P27816 | |
| ENNIPWYQSMFNWNP | 556 | P61550 | |
| PWFSKQWYMNSEAQP | 121 | Q6UW60 | |
| QALYFNDPIWSNMWY | 156 | P29122 | |
| QWVEQEPLMYANWAP | 1046 | Q9UBG0 | |
| PEENPYWWNANMVFI | 166 | Q6P988 | |
| NWTVSYAPDPQNIYW | 406 | Q5T3F8 | |
| NPIIYWLANYVWDML | 1831 | Q9BZC7 | |
| WLANYVWDMLNYLVP | 1836 | Q9BZC7 | |
| NNVYMWEVYYPNLGW | 71 | Q13029 | |
| QEMYQWKAYNPGWPH | 146 | O15296 | |
| EIIPWQMQVLWHPQY | 191 | Q9BS40 | |
| YQPWALPNGWNGQMY | 276 | P31271 | |
| YMWQSEPFRDEPWYN | 316 | P98196 | |
| WQSTPYNDEPWYNQK | 316 | Q8NB49 | |
| VVQWLYQYWPQGQPA | 41 | Q53S58 |